The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management

Recruiting · NCT06909773 · Interventional (participants receive a specific treatment) · Lead sponsor: AstraZeneca

View the official record on ClinicalTrials.gov →

Interventions studied

Guideline education and implementation intervention

What this trial is about

This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) participants , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).

Who can take part

Age range

40 Years and older

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not applicable (e.g. observational or device study)

Study type

Interventional (participants receive a specific treatment)

Inclusion criteria

Give signed written informed consent to participate.
At least 40 years of age at baseline visit.
Previous or newly diagnosed by at least one of the 3 types of CVD which are,
Coronary heart disease ( CHD )
Atrial fibrillation (AF )
Chronic heart failure ( CHF )
Participants can undergo spirometry testing and does not have the following serious diseases or disease states：
Shock within the last 3 months
Mycardial infarction, stroke or unstable angina within last 1 month
Currently suffering from severe HF or severe arrhythmia. Severe HF refers to the need for intravenous administration of vasoactive drugs and diuretics; severe arrhythmia refers to arrhythmias that cause hemodynamic instability, such as ventricular fibrillation and ventricular tachycardia
Severe hemoptysis or active gastrointestinal bleeding within last 1 month
Patients with seizures requiring medication
Patients with hypertensive crisis or uncontrolled hypertension \[systolic blood pressure \> 200 mmHg, diastolic blood pressure \> 100 mmHg (1 mmHg = 0.133 kPa)\]
Patients with active respiratory infectious diseases or infectious diseases, such as open pulmonary tuberculosis, influenza, new coronavirus infection, and acute pneumonia
Patients with aortic or cerebral aneurysms
Pneumothorax and pneumothorax healing within last 1 month
Patients with severe hyperthyroidism
Patients who have recently had eye, ear, cranial or thoracic or abdominal surgery Note: If the patient can cooperate by completing a single, effective forced exhalation (≥6 seconds), then spirometry testing can be performed.
Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.

Exclusion criteria

Significant diseases or conditions, which, in the opinion of the investigator, may put the participant at risk because of participation in the study or may influence either the results of the study or the participant's ability to participate in the study.
Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
Participant who are not able to provide written informed consent.
Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.

Where it is running

60 locations listed.

Research Site - Anqing, China
Research Site - Beijing, China
Research Site - Beijing, China
Research Site - Beijing, China
Research Site - Beijing, China
Research Site - Beijing, China
Research Site - Changsha, China
Research Site - Changsha, China
Research Site - Chaohu, China
Research Site - Chengdu, China
Research Site - Chengdu, China
Research Site - Chengdu, China
Research Site - Chifeng, China
Research Site - Chongqing, China
Research Site - Dalian, China
Research Site - Dingzhou, China
Research Site - Dongguan, China
Research Site - Foshan, China
Research Site - Fuyang, China
Research Site - Fuzhou, China
Research Site - Ganzhou, China
Research Site - Guanghan, China
Research Site - Guangzhou, China
Research Site - Guangzhou, China
Research Site - Guangzhou, China
Research Site - Guangzhou, China
Research Site - Haikou, China
Research Site - Hangzhou, China
Research Site - Hangzhou, China
Research Site - Harbin, China
Research Site - Harbin, China
Research Site - Hefei, China
Research Site - Hefei, China
Research Site - Hubei, China
Research Site - Jinhua, China
Research Site - Jinzhong, China
Research Site - Jiujiang, China
Research Site - Kaiyuan, China
Research Site - Kunming, China
Research Site - Kunming, China
Research Site - Lanzhou, China
Research Site - Leping, China
Research Site - Lianjiang, China
Research Site - Linhai, China
Research Site - Meizhou, China
Research Site - Mianyang, China
Research Site - Nanchang, China
Research Site - Neijiang, China
Research Site - Ningbo, China
Research Site - Ningbo, China
Research Site - Putian, China
Research Site - Quanzhou, China
Research Site - Shanghai, China
Research Site - Shanghai, China
Research Site - Shanghai, China
Research Site - Shanghai, China
Research Site - Shanghai, China
Research Site - Shantou, China
Research Site - Shantou, China
Research Site - Shenyang, China

Showing 60 of 85 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →